Generic placeholder image

Current Pharmaceutical Design

Author(s): Thiago da Silva Honório, Alice Simon, Raiane Monteiro Clacino Machado, Carlos Rangel Rodrigues, Flávia Almada do Carmo, Lucio Mendes Cabral* and Valeria Pereira de Sousa

DOI: 10.2174/0113816128257028231030113156

DownloadDownload PDF Flyer Cite As
Use of In silico Methodologies to Predict the Bioavailability of Oral Suspensions: A Regulatory Approach

Page: [3040 - 3049] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: Oral suspensions are heterogeneous disperse systems, and the particle size distribution, crystalline form of the dispersed solid, and composition of the formulation can be listed as parameters that control the drug dissolution rate and its bioavailability.

Objective: The aim of this work was to develop a discriminative dissolution test, which, in association with in silico methodologies, can make it possible to safely anticipate bioavailability problems.

Methods: Nimesulide and ibuprofen (BCS class II) and cephalexin (BCS class I) oral suspensions were studied. Previously, solid-state structure and particle size in active pharmaceutical ingredients were characterized and the impact of differences on solubility was evaluated for the choice of discriminative medium. Afterwards, particle size distribution (0.1 to 360 μm), dissolution profile, and in vitro permeability in Caco-2 cell of commercial suspensions, were determined. These parameters were used as input for the establishment of the in vitro-in vivo correlation (IVIVC) for the suspensions using the GastroPlus™ with Wagner-Nelson and Loo- Riegelmann deconvolution approach.

Results: The predicted/observed pharmacokinetic model showed good correlation coefficients (r) of 0.960, 0.950, and 0.901, respectively. The IVIVC was established for one nimesulide and two ibuprofen suspensions with r between 0.956 and 0.932, and the percent prediction error (%PE) did not exceed 15%.

Conclusion: In this work, we have performed a complete study combining in vitro/in silico approaches with the aim of anticipating the safety and efficacy of oral pharmaceutical suspensions in order to provide a regulatory tool for this category of products in a faster and more economical way.

[1]
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3): 413-20.
[http://dx.doi.org/10.1023/A:1016212804288] [PMID: 7617530]
[2]
Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract - Influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 2020; 11: 524.
[http://dx.doi.org/10.3389/fphar.2020.00524]
[3]
Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J Clin Pharmacol 2002; 42(6): 620-43.
[http://dx.doi.org/10.1177/00970002042006005] [PMID: 12043951]
[4]
Brown CK, Friedel HD, Barker AR, et al. FIP/AAPS joint workshop report: Dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 2011; 12(2): 782-94.
[http://dx.doi.org/10.1208/s12249-011-9634-x] [PMID: 21688063]
[5]
Food and Drug Administration. Bioavailability and bioequivalence studies submitted in NDAs or INDs - general considerations. 2014. Available From: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations
[6]
Food and Drug Administration. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. 1997. Available From: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms
[7]
Azarmi S, Roa W, Löbenberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm 2007; 328(1): 12-21.
[http://dx.doi.org/10.1016/j.ijpharm.2006.10.001] [PMID: 17084051]
[8]
Pepin XJH, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CE. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets. Mol Pharm 2016; 13(9): 3256-69.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00497] [PMID: 27438964]
[9]
Zhang T, Heimbach T, Lin W, Zhang J, He H. Prospective predictions of human pharmacokinetics for eighteen compounds. J Pharm Sci 2015; 104(9): 2795-806.
[http://dx.doi.org/10.1002/jps.24373] [PMID: 25690565]
[10]
Kostewicz ES, Aarons L, Bergstrand M, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 2014; 57: 300-21.
[http://dx.doi.org/10.1016/j.ejps.2013.09.008] [PMID: 24060672]
[11]
Honório TS, Pinto EC, Rocha HVA, et al. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. AAPS PharmSciTech 2013; 14(3): 1244-54.
[http://dx.doi.org/10.1208/s12249-013-0016-4] [PMID: 23943401]
[12]
Suarez-Sharp S, Li M, Duan J, Shah H, Seo P. Regulatory experience with in vivo in vitro correlations (IVIVC) in new drug applications. AAPS J 2016; 18(6): 1379-90.
[http://dx.doi.org/10.1208/s12248-016-9966-2] [PMID: 27480319]
[13]
Toehwé LH, Da Silva Honorio T, Rodrigues Pereira da Silva LC, et al. Comparison of in vitro, in vivo, and in silico bioavailability results of different prednisone tablet formulations to assess the feasibility of possible biowaiver. Ars Pharmaceutica (Internet) 2021; 62(4): 358-70.
[http://dx.doi.org/10.30827/ars.v62i4.21029]
[14]
Fang Y, Cao W, Xia M, Pan S, Xu X. Study of structure and permeability relationship of flavonoids in Caco-2 cells. Nutrients 2017; 9(12): 1301.
[http://dx.doi.org/10.3390/nu9121301] [PMID: 29186068]
[15]
Jovanović D, Kilibarda V, Todorović V, Potrebić O. A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers. Vojnosanit Pregl 2005; 62(12): 887-93.
[http://dx.doi.org/10.2298/VSP0512887J] [PMID: 16375216]
[16]
Kale P. Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: A randomized three-period, cross-over trial in healthy Indian volunteers. Front Pharmacol 2014; 5: 98.
[http://dx.doi.org/10.3389/fphar.2014.00098] [PMID: 24847268]
[17]
Ginanjar V, Handayani L, Yunaidi D, et al. Bioequivalence study of two formulations of cephalexin powder for oral suspension in healthy subjects under fasting conditions. J Bioequivalence Bioavailab 2021; 13: 1-6.
[18]
Food and Drug Administration. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In vitro/In vivo Correlations. 1997. Available From: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations
[19]
Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009; 49(5): 513-33.
[http://dx.doi.org/10.1177/0091270009333209] [PMID: 19299532]
[20]
Duque MD, Silva DA, Issa MG, Porta V, Löbenberg R, Ferraz HG. In silico prediction of plasma concentrations of fluconazole capsules with different dissolution profiles and bioequivalence study using population simulation. Pharmaceutics 2019; 11(5): 215.
[http://dx.doi.org/10.3390/pharmaceutics11050215] [PMID: 31060289]
[21]
Chilukuri DM, Sunkara G, Young D. Pharmaceutical Product Development In vitro-In vivo Correlation. In: Modi NB, Ed. New York, NY, USA: Routledge 2007; pp. 1-224.
[http://dx.doi.org/10.3109/9781420020175]
[22]
Otsuka M, Fukui Y, Otsuka K, Kim H-J, Ozaki Y. Determination of cephalexin crystallinity and investigation of formation of its amorphous solid by chemoinformetrical near infrared spectroscopy. J Near Infrared Spectrosc 2006; 14(1): 9-16.
[http://dx.doi.org/10.1255/jnirs.581]
[23]
Dokoumetzidis A, Macheras P. A century of dissolution research: From Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 2006; 321(1-2): 1-11.
[http://dx.doi.org/10.1016/j.ijpharm.2006.07.011] [PMID: 16920290]
[24]
Simon A, de Almeida Borges VR, Cabral LM, de Sousa VP. Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension. AAPS PharmSciTech 2013; 14(1): 425-34.
[http://dx.doi.org/10.1208/s12249-012-9920-2] [PMID: 23371786]
[25]
Heng PWS, Wong TW, Cheong WS. Investigation of melt agglomeration process with a hydrophobic binder in combination with sucrose stearate. Eur J Pharm Sci 2003; 19(5): 381-93.
[http://dx.doi.org/10.1016/S0928-0987(03)00138-6] [PMID: 12907289]
[26]
Hiremath P, Nuguru K, Agrahari V. Material attributes and their impact on wet granulation process performance. Handbook of Pharmaceutical Wet Granulation: Theory and Practice in a Quality by Design Paradigm. Amsterdam: Elsevier 2018.
[27]
Metry M, Polli JE. Evaluation of excipient risk in BCS class I and III biowaivers. AAPS J 2022; 24(1): 20.
[http://dx.doi.org/10.1208/s12248-021-00670-1] [PMID: 34988701]
[28]
Grbic S, Lukic V, Kovacevic I, et al. An investigation into the possibilities and limitations of in silico absorption modeling: GastroPlusTM simulation of nimesulide oral absorption. Proceedings of The 2nd Electronic Conference on Pharmaceutical Sciences. Basel, Switzerland. 2012; p. 816.
[http://dx.doi.org/10.3390/ecps2012-00816]
[29]
Katona MT, Nagy-Katona L, Szabó R, Borbás E, Tonka-Nagy P, Takács-Novák K. Multi-compartmental dissolution method, an efficient tool for the development of enhanced bioavailability formulations containing poorly soluble acidic drugs. Pharmaceutics 2023; 15(3): 753.
[http://dx.doi.org/10.3390/pharmaceutics15030753] [PMID: 36986614]
[30]
Tsume Y, Langguth P, Garcia-Arieta A, Amidon GL. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: Ibuprofen and ketoprofen. Biopharm Drug Dispos 2012; 33(7): 366-77.
[http://dx.doi.org/10.1002/bdd.1800] [PMID: 22815122]
[31]
Hu Y, Smith DE. In silico prediction of the absorption and disposition of cefadroxil in humans using an intestinal permeability method scaled from humanized PepT1 mice. Drug Metab Dispos 2019; 47(3): 173-83.
[http://dx.doi.org/10.1124/dmd.118.084236] [PMID: 30593545]
[32]
Okumu A, DiMaso M, Löbenberg R. Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm 2009; 72(1): 91-8.
[http://dx.doi.org/10.1016/j.ejpb.2008.10.019] [PMID: 19056493]
[33]
Parrott N, Lavé T. Prediction of intestinal absorption: Comparative assessment of gastroplus™ and idea™. Eur J Pharm Sci 2002; 17(1-2): 51-61.
[http://dx.doi.org/10.1016/S0928-0987(02)00132-X] [PMID: 12356420]
[34]
Agência Nacional de Vigilância Sanitária. RESOLUÇÃO - RE 1.170, DE 19 DE ABRIL DE 2006. 2006. Available From: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2006/res1170_19_04_2006.html
[35]
Food and Drug Administration. Statistical Approaches to Establishing Bioequivalence 2001. Available From: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence
[36]
Wei H, Dalton C, Dimaso M, Kanfer I, Löbenberg R. Physicochemical characterization of five glyburide powders: A BCS based approach to predict oral absorption. Eur J Pharm Biopharm 2008; 69(3): 1046-56.
[http://dx.doi.org/10.1016/j.ejpb.2008.01.026] [PMID: 18374555]
[37]
da Silva AS, da Rosa Silva CE, Paula FR, da Silva FEB. Discriminative dissolution method for benzoyl metronidazole oral suspension. AAPS PharmSciTech 2016; 17(3): 778-86.
[http://dx.doi.org/10.1208/s12249-015-0407-9] [PMID: 26349689]
[38]
da Fonseca LB, Labastie M, de Sousa VP, Volpato NM. Development and validation of a discriminative dissolution test for nimesulide suspensions. AAPS PharmSciTech 2009; 10(4): 1145-52.
[http://dx.doi.org/10.1208/s12249-009-9320-4] [PMID: 19834814]
[39]
Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The biopharmaceutics classification system: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci 2014; 57: 152-63.
[http://dx.doi.org/10.1016/j.ejps.2014.01.009] [PMID: 24486482]
[40]
Lu Y, Kim S, Park K. In vitro–in vivo correlation: Perspectives on model development. Int J Pharm 2011; 418(1): 142-8.
[http://dx.doi.org/10.1016/j.ijpharm.2011.01.010] [PMID: 21237256]